New combo therapy for bulky tumors enters human testing
NCT ID NCT06349837
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a combination of low dose radiotherapy, focused radiation (SBRT), and the immunotherapy drug tislelizumab in people with large solid tumors that have not responded to standard treatments. The study aims to see if this approach is safe and tolerable. About 24 participants will be enrolled, and the main focus is on side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (a drug that helps the immune system fight cancer), low dose radiotherapy, and stereotactic ablative radiotherapy (focused radiation)
What this could lead to
If successful, this could point toward a new treatment option for people with large tumors that have not responded to standard therapy.
What could go wrong
This is a very early, small Phase 1 trial with only 24 participants, so results may not apply to everyone. The main goal is safety, not effectiveness, and there are risks from radiation and immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••